Mace Rothenberg

Mace L. Rothenberg, M.D., is a physician-executive with more than 30 years of experience in drug development, translational research and risk-benefit assessment. Dr. Rothenberg served as chief medical officer of Pfizer from 2019 to 2021. Prior to that role, Dr. Rothenberg was Pfizer’s head of clinical development & medical affairs for oncology from 2008 to 2016, and chief development officer for oncology from 2016 to 2018. During that time, his organization developed and obtained regulatory approval for 11 new cancer medicines including first-in-class medicines Ibrance (palbociclib) for patients with HR+/HER2- advanced breast cancer and Xalkori (crizotinib) for patients with ALK+ non-small cell lung cancer. Prior to joining Pfizer, Dr. Rothenberg was professor of medicine at Vanderbilt University and Ingram professor of cancer research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, he was associate professor of medicine at the University of Texas Health Science Center at San Antonio and executive officer of the Southwest Oncology Group.

Dr. Rothenberg is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Dr. Rothenberg received his B.A. magna cum laude from the University of Pennsylvania and his M.D. from the New York University School of Medicine. He received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute.